CA2321262A1 - Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes - Google Patents

Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes Download PDF

Info

Publication number
CA2321262A1
CA2321262A1 CA002321262A CA2321262A CA2321262A1 CA 2321262 A1 CA2321262 A1 CA 2321262A1 CA 002321262 A CA002321262 A CA 002321262A CA 2321262 A CA2321262 A CA 2321262A CA 2321262 A1 CA2321262 A1 CA 2321262A1
Authority
CA
Canada
Prior art keywords
mhc
class
major histocompatibility
histocompatibility complex
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002321262A
Other languages
English (en)
Inventor
Kai W. Wucherpfennig
Jack L. Strominger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321262A1 publication Critical patent/CA2321262A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002321262A 1998-02-19 1999-02-19 Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes Abandoned CA2321262A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7535198P 1998-02-19 1998-02-19
US60/075,351 1998-02-19
PCT/US1999/003603 WO1999042597A1 (fr) 1998-02-19 1999-02-19 Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes

Publications (1)

Publication Number Publication Date
CA2321262A1 true CA2321262A1 (fr) 1999-08-26

Family

ID=22125136

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321262A Abandoned CA2321262A1 (fr) 1998-02-19 1999-02-19 Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes

Country Status (8)

Country Link
EP (1) EP1054984A1 (fr)
JP (1) JP2002504342A (fr)
AU (1) AU765378B2 (fr)
BR (1) BR9908082A (fr)
CA (1) CA2321262A1 (fr)
IL (1) IL137706A0 (fr)
NZ (1) NZ506071A (fr)
WO (1) WO1999042597A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889964A1 (fr) 1996-03-28 1999-01-13 The Johns Hopkins University Analogues solubles heterodimeres divalents et multivalents de proteines
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
EP1377609B1 (fr) * 2001-03-14 2015-06-24 Dako Denmark A/S Nouvelles constructions de molecules mhc, methodes d'utilisation de ces constructions a des fins de diagnostic et de therapie et utilisations de molecules mhc
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2486545A1 (fr) * 2001-09-17 2003-03-27 Nalan Utku Peptides capables de moduler une reponse immunitaire
US7175983B2 (en) 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
KR20050044857A (ko) * 2001-11-16 2005-05-13 파멕사 에이/에스 무차별 t 세포 에피토프 삽입물을 갖는 멀티머 단백질의면역원성 모방체
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
EP2204190A1 (fr) * 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha Production d'IgM par des cellules transformées et procédés pour la quantification de ladite production d'IgM
WO2005037190A2 (fr) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Vaccins multiplex
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
EP1688432B1 (fr) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Solution stabilisee a concentration elevee en igm
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
CA2595462A1 (fr) * 2005-01-21 2006-07-27 Nalan Utku Molecules de fusion hla et utilisations associees
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2167537A2 (fr) 2007-07-03 2010-03-31 Dako Denmark A/S Procedes compiles pour analyser et trier des echantillons
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
EP2800582A1 (fr) * 2012-01-06 2014-11-12 Oregon Health & Science University Constructions partielles de cmh et leurs procédés d'utilisation
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN113528634A (zh) 2012-08-14 2021-10-22 10X基因组学有限公司 微胶囊组合物及方法
US9540439B2 (en) 2012-10-08 2017-01-10 St. Jude Children's Research Hospital Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
AU2014214682B2 (en) 2013-02-08 2018-07-26 10X Genomics, Inc. Polynucleotide barcode generation
TR201908418T4 (tr) 2013-11-04 2019-07-22 Uti Lp Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
CA2943624A1 (fr) 2014-04-10 2015-10-15 10X Genomics, Inc. Dispositifs fluidiques, systemes et procedes permettant d'encapsuler et de separer des reactifs, et leurs applications
PL3148580T3 (pl) 2014-05-29 2021-07-12 Macrogenics, Inc. Trójswoiste cząsteczki wiążące, które wiążą się swoiście z wieloma antygenami nowotworowymi, i sposoby ich zastosowania
EP4270006A3 (fr) 2014-06-13 2024-01-10 Immudex ApS Détection générale et isolement de cellules spécifiques par liaison de molécules marquées
KR20230070325A (ko) 2014-06-26 2023-05-22 10엑스 제노믹스, 인크. 개별 세포 또는 세포 개체군으로부터 핵산을 분석하는 방법
AU2016207023B2 (en) 2015-01-12 2019-12-05 10X Genomics, Inc. Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same
EP3262407B1 (fr) 2015-02-24 2023-08-30 10X Genomics, Inc. Procédés et systèmes de traitement de cloisonnement
KR20180011135A (ko) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
MX2018004177A (es) 2015-10-08 2018-09-11 Macrogenics Inc Terapia de combinacion para el tratamiento de cancer.
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN108431232B (zh) 2015-12-04 2022-10-14 10X 基因组学有限公司 用于核酸分析的方法和组合物
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018140966A1 (fr) 2017-01-30 2018-08-02 10X Genomics, Inc. Procédés et systèmes de codage à barres de cellules individuelles sur la base de gouttelettes
US11866465B2 (en) 2017-04-27 2024-01-09 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
US20180340169A1 (en) 2017-05-26 2018-11-29 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
CN109526228B (zh) 2017-05-26 2022-11-25 10X基因组学有限公司 转座酶可接近性染色质的单细胞分析
WO2019099751A1 (fr) 2017-11-15 2019-05-23 10X Genomics, Inc. Perles de gel fonctionnalisées
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
WO2019157529A1 (fr) 2018-02-12 2019-08-15 10X Genomics, Inc. Procédés de caractérisation d'analytes multiples à partir de cellules individuelles ou de populations cellulaires
WO2019195166A1 (fr) 2018-04-06 2019-10-10 10X Genomics, Inc. Systèmes et procédés de contrôle de qualité dans un traitement de cellules uniques
US20220275043A1 (en) * 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3898666A2 (fr) 2018-12-17 2021-10-27 Immudex ApS Panneau comprenant des multimères de borrelia cmh
US20220162695A1 (en) 2020-11-20 2022-05-26 Becton, Dickinson And Company Use of dextramer in single cell analysis
CA3215077A1 (fr) * 2021-04-07 2022-10-13 Thomas J. Malia Multimeres de peptide-mhc-immunoglobuline et leurs procedes d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889964A1 (fr) * 1996-03-28 1999-01-13 The Johns Hopkins University Analogues solubles heterodimeres divalents et multivalents de proteines
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
JP2000516470A (ja) * 1996-08-16 2000-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 可溶性一価および多価mhcクラスii融合タンパク質およびそれらの使用
WO1999009064A1 (fr) * 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Element de la classe ii du complexe majeur d'histocompatibilite portant un epitope/molecules chimeres d'immunoglobuline

Also Published As

Publication number Publication date
WO1999042597A1 (fr) 1999-08-26
JP2002504342A (ja) 2002-02-12
IL137706A0 (en) 2001-10-31
NZ506071A (en) 2003-05-30
AU2774899A (en) 1999-09-06
BR9908082A (pt) 2000-10-31
WO1999042597A9 (fr) 1999-11-04
EP1054984A1 (fr) 2000-11-29
AU765378B2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU765378B2 (en) Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US20050003431A1 (en) Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
AU730457B2 (en) Soluble monovalent and multivalent MHC class II fusion proteins, and uses therefor
KR930002835B1 (ko) 자기면역 개선에 유용한 mhc-중재 독성 포합체
US5468481A (en) MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5260422A (en) MHC conjugates useful in ameliorating autoimmunity
US6270772B1 (en) Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6451314B1 (en) MHC conjugates useful in ameliorating autoimmunity
CA2446408C (fr) Molecules mhc recombinees utiles pour la manipulation de lymphocytes t a specificite antigenique
AU730477B2 (en) MHC binding peptide oligomers and methods of use
JP2009521409A (ja) 制御性t細胞を増殖する方法と組成物
WO2010150233A2 (fr) Polypeptides multimères de hla-g comprenant au moins deux domaines alpha3 et leurs utilisations pharmaceutiques
WO1998005684A9 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
EP0365525B1 (fr) Inhibition de lymphocytes par des peptides hla
EP0630255A1 (fr) Conjugues cmh permettant de traiter l'auto-immunite
JPH09504432A (ja) Mhcタンパク質の原核発現
JP2005514941A (ja) 熱ショックタンパク質に基づく免疫治療の調節
AU2003271276A1 (en) Monovalent, multivalent and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
Reid-Taylor et al. Reconstitution of the glycosylphosphatidylinositol-anchored protein Thy-1: interaction with membrane phospholipids and galactosylceramide
AU2006250976A1 (en) Modified Leukocyte IG-like receptor family members (LIR's) with increased affinity for class I MHC and their uses in modulating T cell activation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued